De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials

Marco Valgimigli(University of Bern), Myeong‐Ki Hong(Ulsan College), Sung‐Jin Hong(Inje University Sanggye Paik Hospital), Zhen Ge(Dalian Medical University), Felice Gragnano(Ospedale Sant'Anna), Peter Jüni(St. Michael's Hospital), Dominick J. Angiolillo(Jacksonville University), Gregg W. Stone(Cardiovascular Research Foundation), Young Bin Song(Samsung Medical Center), Dik Heg, Stephan Windecker, George Dangas, Shamir R. Mehta(Population Health Research Institute), Pascal Vranckx(Jessa Hospital), Sergio Leonardi(Policlinico San Matteo Fondazione), Renato D. Lópes(Duke University), Bruno R. da Costa(University of Oxford), Konstantina Chalkou(University of Bern), Hyeon‐Cheol Gwon(Samsung Medical Center), Joo‐Yong Hahn(Samsung Medical Center), Anna Franzone(University Hospital of Bern), Usman Baber(University of Oklahoma Health Sciences Center), Michael C. Gibson(Beth Israel Deaconess Medical Center), Shao-Liang Chen(Nanjing Medical University), Eugène McFadden(Skadden Arps Slate Meagher & Flom), Paolo Calabrò(University of Campania "Luigi Vanvitelli"), Byeong‐Keuk Kim(Ewha Womans University), Roxana Mehran(Icahn School of Medicine at Mount Sinai), Yangsoo Jang(Yonsei University)
The Lancet
August 31, 2024
Cited by 93


Related Papers